Advertiser / Brand
Revolution Beauty vs URSAPHARM
Structured technology and market comparison · 2026
Direct Feature Comparison
Revolution Beauty · vs · URSAPHARMPublic beauty brand selling makeup, skincare and haircare products.
German ophthalmic pharmaceutical manufacturer with international distribution.
Analyze all overlapping signals and tech stacks for Revolution Beauty and URSAPHARM
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Revolution Beauty and URSAPHARM?
When comparing Revolution Beauty and URSAPHARM, both platforms operate within the Advertiser / Brand ecosystem. Revolution Beauty is positioned as Public beauty brand selling makeup, skincare and haircare products, whereas URSAPHARM focuses on German ophthalmic pharmaceutical manufacturer with international distribution. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Revolution Beauty and URSAPHARM?
When evaluating Revolution Beauty and URSAPHARM, enterprise buyers also consider other platforms in Advertiser / Brand. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Revolution Beauty and URSAPHARM compare?
Revolution Beauty is headquartered in GB (founded in 2014) with 201–500 employees. URSAPHARM is based in DE (founded in 1974) with 501–1,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Revolution Beauty vs URSAPHARM
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Revolution Beauty
Recent Signals
- ·SEC APIfinancials
8-K Financial Filing Analysis for Revolution Beauty (2026-08-19)
On August 17, 2026, the Compensation Committee of Revelation Biosciences, Inc. approved material restricted stock grants to executive leadership under its Amended and Restated 2021 Equity Incentive Plan. Chief Executive Officer James Rolke received 208,076 restricted shares, and Chief Financial Officer Chester S. Zygmont, III was granted 208,073 restricted shares. The equity awards are structured to vest across four equal 25% tranches linked to either reaching market capitalization hurdles of $30 million, $60 million, $90 million, and $120 million for 20 consecutive trading days, or time-based vesting at the two-year and four-year marks. The package aligns executive compensation with aggressive market valuation targets while providing retention security.
- CEO James Rolke and CFO Chester S. Zygmont, III were granted 208,076 and 208,073 restricted shares, respectively, under the 2021 Equity Incentive Plan.
- Awards vest in four equal 25% tranches upon reaching market capitalization thresholds of $30M, $60M, $90M, and $120M sustained over 20 consecutive trading days, or alternatively at 2-year (first two tranches) and 4-year (final two tranches) time intervals.
- Grants include standard accelerated vesting protections upon a Change in Control or qualified involuntary termination events.
URSAPHARM
Recent Signals
- ·URSAPHARM
URSAPHARM und der FC Bayern bauen erfolgreiche Partnerschaft weiter aus
Die URSAPHARM Arzneimittel GmbH und der FC Bayern München setzen ihre erfolgreiche Zusammenarbeit fort. Mit HYLO®, dem marktführenden Sortiment im Bereich der Befeuchtung trockener Augen, bleibt URSAPHARM bis 2029 Gold Partner der ersten Herrenmannschaft des deutschen Rekordmeisters. Gleichzeitig wird die Partnerschaft strategisch ausgebaut: Neben einer stärkeren Ausrichtung auf die asiatischen Märkte […]
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Revolution Beauty and URSAPHARM share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks